Skip to main content

Agilent, Incyte Genomics, Zuhong Lu


Agilent has received US Patent Number 6,421,668, “Method and system for partitioning data into subsets of related data.” This patent covers methods in which arbitrary metrics are applied to different data entities to partition them into subsets in several iterations. During each iteration, candidate entities with high affinities toward the subset are added, and those for which affinities have decreased are removed. The aim is to obtain an optimal or near-optimal partitioning of data.


Incyte Genomics has received two US Patents, Number 6,424,921, “Averaging multiple hybridization arrays,” and 6,423,535, “Normalization control for hybridization reactions.” The first patent describes a method in which microarray data is combined into “composite hybridization arrays,” — groups of selected data from dual-channel hybridization microarrays — or “averaged hybridization arrays”, averaged values from multiple arrays, in an array database. These arrays are used for searching, analysis, and data processing. The second patent describes methods and kits for determining the amount of polynucleotides in a sample. In one of these methods, probes and double- or single-stranded complements to the targets are hybridized to the target. The hybridization pattern to the probe and the hybridization pattern from the standard sequences are compared in order to quantify the polynucleotides.


Zuhong Lu of Nanjing, China has received US Patent Number 6,423,552, “Method for the preparation of compound micro array chips and the compound micro array chips produced according to said method.” The method involves stamping reagents on fixed locations on a microarray substrate repeatedly, in order to produce chemical microarray chips, and describes the chips that are produced. The method is designed to be low-cost and simple.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.